Fennec Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	38.79	47.54	21.25	1.54	-	0.17
Revenue Growth (YoY)	-21.39%	123.69%	1284.50%	-	-	-
Cost of Revenue	2.67	3.18	1.26	0.09	-	-
Gross Profit	36.12	44.35	19.99	1.45	-	0.17
Selling, General & Admin	40.5	41.48	32.71	20.51	12.24	12.95
Research & Development	0.28	0.31	0.06	3.53	4.98	5.11
Operating Expenses	40.78	41.79	32.76	24.04	17.22	18.06
Operating Income	-4.66	2.57	-12.77	-22.59	-17.22	-17.89
Interest Expense	-2.8	-4.16	-3.68	-1.13	-0.14	-0.41
Interest & Investment Income	0.96	1.68	0.44	0.2	0.05	0.09
Currency Exchange Gain (Loss)	-	-0.08	0.01	-0.01	-0.01	-
EBT Excluding Unusual Items	-6.51	0.01	-16.01	-23.53	-17.32	-18.21
Gain (Loss) on Sale of Investments	-0.07	-0.08	-0.04	-0.18	-0.03	0.1
Pretax Income	-6.57	-0.07	-16.05	-23.71	-17.35	-18.11
Income Tax Expense	0.37	0.37	-	-	-	-
Net Income	-6.94	-0.44	-16.05	-23.71	-17.35	-18.11
Net Income to Common	-6.94	-0.44	-16.05	-23.71	-17.35	-18.11
Shares Outstanding (Basic)	28	27	27	26	26	24
Shares Outstanding (Diluted)	28	27	27	26	26	24
Shares Change (YoY)	1.25%	2.71%	1.14%	1.03%	9.71%	19.14%
EPS (Basic)	-0.25	-0.02	-0.60	-0.90	-0.67	-0.76
EPS (Diluted)	-0.26	-0.02	-0.60	-0.90	-0.67	-0.76
Gross Margin	93.12%	93.30%	94.08%	94.40%	-	100.00%
Operating Margin	-12.02%	5.40%	-60.09%	-1471.60%	-	-10520.59%
Profit Margin	-17.89%	-0.92%	-75.50%	-1544.89%	-	-10652.35%
EBITDA	-4.33	3.6	-	-	-	-
EBITDA Margin	-11.15%	7.57%	-	-	-	-
D&A For EBITDA	0.34	1.03	-	-	-	-
EBIT	-4.66	2.57	-12.77	-22.59	-17.22	-17.89
EBIT Margin	-12.02%	5.40%	-60.09%	-	-	-
Revenue as Reported	38.79	47.54	21.25	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.